GH Research PLC – NASDAQ:GHRS
GH Research stock price today
$12.7
+5.57
+78.37%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
GH Research stock price monthly change
-40.62%
month
GH Research stock price quarterly change
-40.62%
quarter
GH Research stock price yearly change
+29.45%
year
GH Research key metrics
Market Cap | 363.67M |
Enterprise value | N/A |
P/E | -17.19 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 1.63 |
PEG ratio | -0.17 |
EPS | -0.63 |
Revenue | N/A |
EBITDA | -36.96M |
Income | -32.31M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGH Research stock price history
GH Research stock forecast
GH Research financial statements
Average Price Target
$28
Potential upside: 120.47%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -7.72M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.64M | |
| Dec 2023 | 0 | -11.27M | |
| Mar 2024 | 80K | -7.66M | -9582.5% |
| 2023-11-09 | -0.2 | -0.11 |
|---|---|---|
| 2024-02-29 | -0.2 | -0.21 |
| 2024-05-03 | -0.22 | -0.15 |
| Jun 2023 | 240272000 | 7.28M | 3.03% |
|---|---|---|---|
| Sep 2023 | 232568000 | 6.79M | 2.92% |
| Dec 2023 | 226300000 | 6.70M | 2.96% |
| Mar 2024 | 217583000 | 7.83M | 3.6% |
| Jun 2023 | -8.02M | -46K | -37K |
|---|---|---|---|
| Sep 2023 | -10.34M | -8K | -56K |
| Dec 2023 | -8.08M | -24K | -41K |
| Mar 2024 | -9.59M | 8.78M | -71K |
GH Research alternative data
| Aug 2023 | 32 |
|---|---|
| Sep 2023 | 32 |
| Oct 2023 | 32 |
| Nov 2023 | 32 |
| Dec 2023 | 32 |
| Jan 2024 | 32 |
| Feb 2024 | 32 |
| Mar 2024 | 49 |
| Apr 2024 | 49 |
| May 2024 | 49 |
| Jun 2024 | 49 |
| Jul 2024 | 49 |
GH Research other data
12.82%
-57.90%
of GHRS is owned by hedge funds
12
-20
6.66M
-24.22M
shares is hold by hedge funds
-
What's the price of GH Research stock today?
One share of GH Research stock can currently be purchased for approximately $12.7.
-
When is GH Research's next earnings date?
Unfortunately, GH Research's (GHRS) next earnings date is currently unknown.
-
Does GH Research pay dividends?
No, GH Research does not pay dividends.
-
How much money does GH Research make?
GH Research has a market capitalization of 363.67M. GH Research made a loss 35.59M US dollars in net income (profit) last year or -$0.15 on an earnings per share basis.
-
What is GH Research's stock symbol?
GH Research PLC is traded on the NASDAQ under the ticker symbol "GHRS".
-
What is GH Research's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of GH Research?
Shares of GH Research can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does GH Research have?
As Jul 2024, GH Research employs 49 workers.
-
When GH Research went public?
GH Research PLC is publicly traded company for more then 4 years since IPO on 25 Jun 2021.
-
What is GH Research's official website?
The official website for GH Research is ghres.com.
-
How can i contact GH Research?
GH Research can be reached via phone at +353 1 437 8443.
-
What is GH Research stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for GH Research in the last 12 months, the avarage price target is $28. The average price target represents a 120.47% change from the last price of $12.7.
GH Research company profile:
GH Research PLC
ghres.comExchange:
NASDAQ
Full time employees:
49
Industry:
Biotechnology
Sector:
Healthcare
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
28 Baggot Street Lower
Dublin, D02 NX43
Dublin, D02 NX43
CIK: 0001855129
ISIN: IE000GID8VI0
CUSIP: G3855L106
